Profile data is unavailable for this security.
About the company
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
- Revenue in USD (TTM)100.33bn
- Net income in USD31.37bn
- LocationPfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
- Phone+1 (212) 733-2323
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|PFE:NYQ since |
|Seagen Inc||Announced||13 Mar 2023||13 Mar 2023Announced||3.60%||43.84bn|
|Global Blood Therapeutics Inc||Deal completed||08 Aug 2022||08 Aug 2022Deal completed||-17.17%||5.07bn|
|Biohaven Pharmaceutical Holding Co Ltd||Deal completed||10 May 2022||10 May 2022Deal completed||-16.10%||12.60bn|
|ReViral Ltd||Deal completed||07 Apr 2022||07 Apr 2022Deal completed||-22.81%||525.00m|